Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics and precision medicine company that sells germline and tumor-based genetic tests used to assess cancer risk, guide treatment selection, and inform reproductive and mental-health decisions. Its oncology franchise includes the MyRisk Hereditary Cancer test, BRACAnalysis CDx and MyChoice CDx companion diagnostics, the Prolaris prostate cancer prognostic test, EndoPredict for breast cancer, and the Precise Tumor molecular profile, alongside Precise MRD for residual disease monitoring; GeneSight covers psychotropic medication selection, and the Prenatal Health business houses Prequel, Foresight, SneakPeek and FirstGene. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad listed on Nasdaq in October 1995 and employs roughly 2,700 people. In October 2026 the company signed a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash, a portfolio that served more than 600,000 patients in the trailing twelve months, with the transaction expected to close by early 2027 and proceeds directed at the cancer-care franchise.